Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) was $2.53 for the day, up 2.02% from the previous closing price of $2.48. In other words, the price has increased by $2.02 from its previous closing price. On the day, 1.03 million shares were traded.
Ratios:
Our analysis of ZNTL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.29 and its Current Ratio is at 7.29. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
On June 20, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $28 to $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 06 ’25 when Bruns Ingmar bought 20,000 shares for $2.28 per share. The transaction valued at 45,656 led to the insider holds 36,629 shares of the business.
Cam Gallagher bought 687 shares of ZNTL for $1,374 on Feb 11 ’25. On Feb 03 ’25, another insider, Vultaggio Vincent, who serves as the PAO and Interim PFO of the company, sold 2,615 shares for $1.71 each. As a result, the insider received 4,476 and left with 189,826 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.45 while its Price-to-Book (P/B) ratio in mrq is 0.51.
Stock Price History:
Over the past 52 weeks, ZNTL has reached a high of $18.07, while it has fallen to a 52-week low of $1.61. The 50-Day Moving Average of the stock is -4.98%, while the 200-Day Moving Average is calculated to be -44.72%.
Shares Statistics:
A total of 71.15M shares are outstanding, with a floating share count of 52.67M. Insiders hold about 26.09% of the company’s shares, while institutions hold 87.48% stake in the company.
